We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
+42.01%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$6.4B
AUM Growth
+$1.32B
(+26%)
Cap. Flow
-$45.9M
Cap. Flow
% of AUM
-0.72%
Top 10 Holdings %
Top 10 Hldgs %
60.92%
Holding
71
New
5
Increased
8
Reduced
9
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$208M |
| 2 |
Structure Therapeutics
GPCR
|
+$27.9M |
| 3 |
MacroGenics
MGNX
|
+$25.7M |
| 4 |
UroGen Pharma
URGN
|
+$20.8M |
| 5 |
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
|
+$11.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$62.6M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$61M |
| 3 |
CVAC
CureVac
CVAC
|
+$42.6M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$36.6M |
| 5 |
Viridian Therapeutics
VRDN
|
+$30.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Miscellaneous | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Arvinas
ARVN
$540M
| $17.3M | 0.27% |
+421,348
| New | +$9.85M |
|
|
HARP
52
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $17.1M | 0.27% |
+1,500,000
| New | +$11.8M |
|
|
BCYC
53
Bicycle Therapeutics
BCYC
$257M
| $14.5M | 0.23% |
800,000
| – | – |
|
|
CVAC
54
DELISTED
CureVac
CVAC
| $11.6M | 0.18% |
2,744,270
-7,860,074
| -74% | -$42.6M |
|
|
CMPS
55
Compass Pathways
CMPS
$1.91B
| $11.3M | 0.18% |
1,286,000
| – | – |
|
56
Black Diamond Therapeutics
BDTX
$113M
| $9.91M | 0.15% |
3,525,754
| – | – |
|
|
CMRX
57
DELISTED
Chimerix, Inc.
CMRX
| $8.47M | 0.13% |
8,800,000
+2,298,376
| +35% | +$2.23M |
|
|
IGMS
58
DELISTED
IGM Biosciences
IGMS
| $7.79M | 0.12% |
937,500
| – | – |
|
|
CNTB
59
Connect Biopharma Holdings
CNTB
$73.7M
| $3.61M | 0.06% |
3,062,871
-3,928,132
| -56% | -$4.66M |
|
60
Unicycive Therapeutics
UNCY
$131M
| $3.01M | 0.05% |
347,069
| – | – |
|
61
SAB Biotherapeutics
SABS
$310M
| $1.63M | 0.03% |
+237,408
| New | +$1.99M |
|
62
NewAmsterdam Pharma Warrant
NAMSW
$52.3M
| $1.04M | 0.02% |
333,333
| – | – |
|
63
Aclaris Therapeutics
ACRS
$814M
| – | – |
-4,398,453
| Closed | -$30.1M |
|
64
Celcuity
CELC
$4.05B
| – | – |
-1,400,001
| Closed | -$12.8M |
|
|
65
Cogent Biosciences
COGT
$5.68B
| – | – |
-6,416,147
| Closed | -$62.6M |
|
66
EyePoint Inc
EYPT
$316M
| – | – |
-3,370,506
| Closed | -$26.9M |
|
67
Nektar Therapeutics
NKTR
$2.28B
| – | – |
-1,246,667
| Closed | -$11.1M |
|
|
SLNO
68
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-1,239,000
| Closed | -$36.6M |
|
|
TRML
69
DELISTED
Tourmaline Bio
TRML
| – | – |
-240,324
| Closed | -$6.75M |
|
|
70
Viridian Therapeutics
VRDN
$2.47B
| – | – |
-2,007,946
| Closed | -$30.8M |
|
|
NSTG
71
DELISTED
NanoString Technologies, Inc.
NSTG
| – | – |
-1,723,373
| Closed | -$2.96M |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, RA Capital Management held 71 positions worth $6.4B, up 26% from $5.08B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
RA Capital Management's Q4 2023 filing shows 5 new, 8 increased, 9 reduced and 9 closed positions. Its largest new stake was Structure Therapeutics: 486,832 shares worth $19.8M. The largest sale was Cogent Biosciences, an estimated $62.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
- RA Capital Management's largest Q4 2023 buy was Structure Therapeutics: 486,832 shares worth $19.8M.
- RA Capital Management added most to Immunogen Inc in Q4 2023, an estimated $208M increase.
- RA Capital Management's biggest Q4 2023 reduction was Ascendis Pharma A/S, cutting an estimated $61M.
- RA Capital Management fully exited Cogent Biosciences in Q4 2023, selling an estimated $62.6M.
- RA Capital Management's ten largest holdings make up 61% of its $6.4B portfolio in Q4 2023.
- RA Capital Management opened 5 new positions and closed 9 in Q4 2023.
- RA Capital Management's portfolio value rose 26% quarter-over-quarter to $6.4B.
Based on RA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.